Table 3.
Prediction of pathological complete remission with Ki67, using multiple linear regression analysis (extended final model)
| Characteristic | OR | 95% CI | P |
|---|---|---|---|
| pT | |||
| 1 | 1 | - | - |
| 2-4 | 0.34 | 0.18-0.65 | < 0.01 |
| Grading | |||
| 1-2 | 1 | - | - |
| 3 | 2.51 | 1.41-4.49 | < 0.01 |
| Estrogen receptor status | |||
| Negative | 1 | - | - |
| Positive | 0.30 | 0.14-0.63 | < 0.01 |
| Progesterone receptor status | |||
| Negative | 1 | - | - |
| Positive | 0.50 | 0.22-1.14 | 0.10 |
| HER2/neu receptor status | |||
| Negative | 1 | - | - |
| Positive | 2.37 | 1.33-4.22 | < 0.01 |
| Ki67 | |||
| Low | 1 | - | - |
| High | 3.51 | 1.41-10.10 | 0.01 |
CI, confidence intervals; OR, odds ratio; pT, pathological tumor stage (TNM classification).